We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Diabetes

Journal Scan / Research · February 10, 2021

Sotagliflozin Plus Insulin in Poorly Controlled T1D

Diabetes Technology & Therapeutics

 

Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes Technology & Therapeutics
Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study
Diabetes Technol. Ther. 2021 Jan 01;23(1)59-69, BW Bode, E Cengiz, RP Wadwa, P Banks, T Danne, JA Kushner, DK McGuire, AL Peters, P Strumph, S Sawhney

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading